Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT05169762
Recruiting Observational

Feminizing Treatment in Transgender Women and Non-binary Persons

NCT05169762 · tracked via the Priya Life Science Denmark tracker
Sponsor
Odense University Hospital
Phase
Observational
Started
2022-02-01
Last updated
2025-03-21

Condition(s) studied

Transgenderism

Investigational drug(s) / intervention(s)

standard treatment

standard treatment: starndard treatment for transgender women

Study summary

Cohort study in 100 transgender women treated with gender affirming hormone treatment. Follow up affter 1year, 3 years, 5 years and 10 years, Outcomes regarding cardiovascular effects of hormone treatment.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * assigned male at birth and eligeble for gender affirming feminizing treatment Exclusion Criteria: none \-

Primary outcome measure(s)

  • coronary plaque formation — 1 year
    mm3

Trial sites (1)

FacilityCityRegionStatus
OdenseUH Odense Denmark Recruiting

More Odense University Hospital trials in Denmark

Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease Enrolling by invitation
Continuous Bloodsugar Monitoring System With a Sensor Compared to Fingerstick Bloodsugar Monitoring Recruiting
Immunotherapy in Patients With Early dMMR Rectal Cancer Recruiting
Permissive Hyperthermia in Acute Brain Injury Active, not recruiting
Vitamin D and Angiogenic Markers in Odense Child Cohort 1 Active, not recruiting

Other trials for the same condition

Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05169762 on ClinicalTrials.gov ↗ ← All trials in Denmark